CureVac (CVAC) Competitors $3.43 -0.12 (-3.38%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. MOR, SRRK, PTGX, CRNX, SWTX, OGN, CPRX, VKTX, XENE, and MLTXShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. CureVac vs. MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals MoonLake Immunotherapeutics CureVac (NASDAQ:CVAC) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends. Which has more volatility & risk, CVAC or MOR? CureVac has a beta of 2.48, suggesting that its stock price is 148% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Do institutionals and insiders believe in CVAC or MOR? 17.3% of CureVac shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in CVAC or MOR? CureVac received 2 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 56.25% of users gave CureVac an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformCureVacOutperform Votes2756.25% Underperform Votes2143.75% MorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Which has stronger earnings & valuation, CVAC or MOR? MorphoSys has lower revenue, but higher earnings than CureVac. MorphoSys is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$535.18M1.49-$281.58M$0.824.33MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media refer more to CVAC or MOR? In the previous week, CureVac had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for CureVac and 0 mentions for MorphoSys. CureVac's average media sentiment score of 0.51 beat MorphoSys' score of 0.00 indicating that CureVac is being referred to more favorably in the media. Company Overall Sentiment CureVac Positive MorphoSys Neutral Do analysts rate CVAC or MOR? CureVac presently has a consensus target price of $14.00, suggesting a potential upside of 294.37%. Given CureVac's stronger consensus rating and higher probable upside, equities research analysts plainly believe CureVac is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CVAC or MOR more profitable? CureVac has a net margin of 20.72% compared to MorphoSys' net margin of -226.79%. CureVac's return on equity of 21.98% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets CureVac20.72% 21.98% 15.72% MorphoSys -226.79%-694.31%-22.55% SummaryCureVac beats MorphoSys on 15 of the 18 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$796.40M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio6.457.4422.4818.48Price / Sales1.49242.70394.56103.59Price / CashN/A65.8538.1834.62Price / Book1.426.516.774.25Net Income-$281.58M$143.21M$3.22B$248.23M7 Day Performance8.90%1.98%1.48%0.89%1 Month Performance30.51%6.89%3.99%3.53%1 Year Performance33.96%-2.52%16.15%5.08% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac3.9582 of 5 stars$3.43-3.4%$14.00+308.2%+40.9%$770.60M$535.18M6.25880Analyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0551 of 5 stars$29.81-3.1%$42.67+43.1%+124.3%$2.83B$33.19M-12.69140Upcoming EarningsInsider TradeNews CoveragePositive NewsPTGXProtagonist Therapeutics3.4638 of 5 stars$45.80-1.0%$65.44+42.9%+82.5%$2.81B$434.43M17.22120Upcoming EarningsNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6563 of 5 stars$30.15-0.9%$73.00+142.1%-23.8%$2.81B$1.04M-8.08210Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9492 of 5 stars$37.06-2.3%$73.20+97.5%-0.8%$2.78B$191.59M-10.65230Analyst ForecastNews CoverageOGNOrganon & Co.4.7633 of 5 stars$10.67-4.0%$20.60+93.1%-30.5%$2.75B$6.40B3.2010,000Earnings ReportOptions VolumeNews CoverageGap DownCPRXCatalyst Pharmaceuticals4.6817 of 5 stars$22.02-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6680Upcoming EarningsNews CoveragePositive NewsVKTXViking Therapeutics4.4972 of 5 stars$23.72-0.9%$89.75+278.4%-63.7%$2.66BN/A-23.7220Analyst ForecastOptions VolumeAnalyst RevisionXENEXenon Pharmaceuticals2.5911 of 5 stars$34.70-1.2%$56.78+63.6%-6.0%$2.66B$9.43M-12.30210Upcoming EarningsOptions VolumePositive NewsMLTXMoonLake Immunotherapeutics1.5529 of 5 stars$40.00+4.4%$80.50+101.3%+2.9%$2.56BN/A-31.012Upcoming EarningsAnalyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies MOR Competitors SRRK Competitors PTGX Competitors CRNX Competitors SWTX Competitors OGN Competitors CPRX Competitors VKTX Competitors XENE Competitors MLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CVAC Stock Free CVAC Stock Alerts